1
|
Dongol A, Xie Y, Zheng P, Chen X, Huang XF. Olanzapine attenuates amyloid-β-induced microglia-mediated progressive neurite lesions. Int Immunopharmacol 2024; 137:112469. [PMID: 38908083 DOI: 10.1016/j.intimp.2024.112469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Revised: 06/06/2024] [Accepted: 06/10/2024] [Indexed: 06/24/2024]
Abstract
The accumulation of amyloid-β (Aβ) in the brain is the first pathological mechanism to initiate Alzheimer's disease (AD) pathogenesis. However, the precise role of Aβ in the disease progression remains unclear. Through decades of research, prolonged inflammation has emerged as an important core pathology in AD. Previously, a study has demonstrated the neurotoxic effect of Aβ-induced neuroinflammation in neuron-glia co-culture at 72 h. Here, we hypothesise that initial stage Aβ may trigger microglial inflammation, synergistically contributing to the progression of neurite lesions relevant to AD progression. In the present study, we aimed to determine whether olanzapine, an antipsychotic drug possessing anti-inflammatory properties, can ameliorate Aβ-induced progressive neurite lesions. Our study reports that Aβ induces neurite lesions with or without inflammatory microglial cells in vitro. More intriguingly, the present study revealed that Aβ exacerbates neurite lesions in synergy with microglia. Moreover, the time course study revealed that Aβ promotes microglia-mediated neurite lesions by eliciting the secretion of pro-inflammatory cytokines. Furthermore, our study shows that olanzapine at lower doses prevents Aβ-induced microglia-mediated progressive neurite lesions. The increase in pro-inflammatory cytokines induced by Aβ is attenuated by olanzapine administration, associated with a reduction in microglial inflammation. Finally, this study reports that microglial senescence induced by Aβ was rescued by olanzapine. Thus, our study provides the first evidence that 1 µM to 5 µM of olanzapine can effectively prevent Aβ-induced microglia-mediated progressive neurite lesions by modulating microglial inflammation. These observations reinforce the potential of targeting microglial remodelling to slow disease progression in AD.
Collapse
Affiliation(s)
- Anjila Dongol
- School of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong, Northfields Avenue, NSW 2522, Australia
| | - Yuanyi Xie
- School of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong, Northfields Avenue, NSW 2522, Australia
| | - Peng Zheng
- School of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong, Northfields Avenue, NSW 2522, Australia
| | - Xi Chen
- School of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong, Northfields Avenue, NSW 2522, Australia
| | - Xu-Feng Huang
- School of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong, Northfields Avenue, NSW 2522, Australia.
| |
Collapse
|
2
|
Yamamoto K, Tsuji M, Oguchi T, Momma Y, Ohashi H, Ito N, Nohara T, Nakanishi T, Ishida A, Hosonuma M, Nishikawa T, Murakami H, Kiuchi Y. Comparison of Protective Effects of Antidepressants Mediated by Serotonin Receptor in Aβ-Oligomer-Induced Neurotoxicity. Biomedicines 2024; 12:1158. [PMID: 38927365 PMCID: PMC11200737 DOI: 10.3390/biomedicines12061158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2024] [Revised: 05/16/2024] [Accepted: 05/20/2024] [Indexed: 06/28/2024] Open
Abstract
Amyloid β-peptide (Aβ) synthesis and deposition are the primary factors underlying the pathophysiology of Alzheimer's disease (AD). Aβ oligomer (Aβo) exerts its neurotoxic effects by inducing oxidative stress and lesions by adhering to cellular membranes. Though several antidepressants have been investigated as neuroprotective agents in AD, a detailed comparison of their neuroprotection against Aβo-induced neurotoxicity is lacking. Here, we aimed to elucidate the neuroprotective effects of clinically prescribed selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and noradrenergic and specific serotonergic antidepressants at the cellular level and establish the underlying mechanisms for their potential clinical applications. Therefore, we compared the neuroprotective effects of three antidepressants, fluoxetine (Flx), duloxetine (Dlx), and mirtazapine (Mir), by their ability to prevent oxidative stress-induced cell damage, using SH-SY5Y cells, by evaluating cell viability, generation of reactive oxygen species (ROS) and mitochondrial ROS, and peroxidation of cell membrane phospholipids. These antidepressants exhibited potent antioxidant activity (Dlx > Mir > Flx) and improved cell viability. Furthermore, pretreatment with a 5-hydroxytryptamine 1A (5-HT1A) antagonist suppressed their effects, suggesting that the 5-HT1A receptor is involved in the antioxidant mechanism of the antidepressants' neuroprotection. These findings suggest the beneficial effects of antidepressant treatment in AD through the prevention of Aβ-induced oxidative stress.
Collapse
Affiliation(s)
- Ken Yamamoto
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Mayumi Tsuji
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan
| | - Tatsunori Oguchi
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan
| | - Yutaro Momma
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Hideaki Ohashi
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Naohito Ito
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Tetsuhito Nohara
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Tatsuya Nakanishi
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Atsushi Ishida
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Masahiro Hosonuma
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan
| | - Toru Nishikawa
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan
| | - Hidetomo Murakami
- Department of Neurology, Showa University School of Medicine, Tokyo 142-8666, Japan; (Y.M.); (H.O.); (N.I.); (T.N.); (H.M.)
| | - Yuji Kiuchi
- Department of Pharmacology, Showa University Graduate School of Medicine, Tokyo 142-8555, Japan; (K.Y.); (T.O.); (T.N.); (A.I.); (M.H.); (T.N.); (Y.K.)
- Pharmacological Research Center, Showa University, Tokyo 142-8555, Japan
| |
Collapse
|
4
|
Correia AS, Fraga S, Teixeira JP, Vale N. Cell Model of Depression: Reduction of Cell Stress with Mirtazapine. Int J Mol Sci 2022; 23:ijms23094942. [PMID: 35563333 PMCID: PMC9099543 DOI: 10.3390/ijms23094942] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 04/26/2022] [Accepted: 04/27/2022] [Indexed: 01/05/2023] Open
Abstract
Depression is a very prevalent and complex disease. This condition is associated with a high rate of relapse, making its treatment a challenge. Thus, an intensive investigation of this disease and its treatment is necessary. In this work, through cell viability assays (MTT and neutral red assays) and alkaline comet assays, we aimed to test the induction of stress in human SH-SY5Y cells through the application of hydrocortisone and hydrogen peroxide and to test the reversal or attenuation of this stress through the application of mirtazapine to the cells. Our results demonstrated that hydrogen peroxide, and not hydrocortisone, can induce cellular stress, as evidenced by DNA damage and a global cellular viability reduction, which were alleviated by the antidepressant mirtazapine. The establishment of a cellular model of depression through stress induction is important to study new possibilities of treatment of this disease using cell cultures.
Collapse
Affiliation(s)
- Ana Salomé Correia
- OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Plácido da Costa, 4200-450 Porto, Portugal;
- Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
| | - Sónia Fraga
- Department of Environmental Health, National Institute of Health Dr. Ricardo Jorge, 4000-053 Porto, Portugal; (S.F.); (J.P.T.)
- EPIUnit-Instituto de Saúde Pública, University of Porto, 4050-600 Porto, Portugal
- Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), 4050-600 Porto, Portugal
| | - João Paulo Teixeira
- Department of Environmental Health, National Institute of Health Dr. Ricardo Jorge, 4000-053 Porto, Portugal; (S.F.); (J.P.T.)
- EPIUnit-Instituto de Saúde Pública, University of Porto, 4050-600 Porto, Portugal
- Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), 4050-600 Porto, Portugal
| | - Nuno Vale
- OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Plácido da Costa, 4200-450 Porto, Portugal;
- Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
- Associate Laboratory RISE—Health Research Network, Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
- Correspondence:
| |
Collapse
|
5
|
Correia AS, Vale N. Antidepressants in Alzheimer's Disease: A Focus on the Role of Mirtazapine. Pharmaceuticals (Basel) 2021; 14:ph14090930. [PMID: 34577630 PMCID: PMC8467729 DOI: 10.3390/ph14090930] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 09/07/2021] [Accepted: 09/14/2021] [Indexed: 12/21/2022] Open
Abstract
Mirtazapine belongs to the category of antidepressants clinically used mainly in major depressive disorder but also used in obsessive-compulsive disorders, generalized anxiety, and sleep disturbances. This drug acts mainly by antagonizing the adrenergic α2, and the serotonergic 5-HT2 and 5-HT3 receptors. Neuropsychiatric symptoms, such as depression and agitation, are strongly associated with Alzheimer’s disease, reducing the life quality of these patients. Thus, it is crucial to control depression in Alzheimer’s patients. For this purpose, drugs such as mirtazapine are important in the control of anxiety, agitation, and other depressive symptoms in these patients. Indeed, despite some contradictory studies, evidence supports the role of mirtazapine in this regard. In this review, we will focus on depression in Alzheimer’s disease, highlighting the role of mirtazapine in this context.
Collapse
Affiliation(s)
- Ana Salomé Correia
- OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal;
- Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal
| | - Nuno Vale
- OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal;
- Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal
- Correspondence:
| |
Collapse
|